This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Danaher (DHR) Provides Improved Q4 Core Revenue Growth Guidance
by Zacks Equity Research
Benefiting from strong growth in Cepheid's molecular diagnostics among other factors, Danaher (DHR) improves its adjusted core revenue growth guidance for the fourth quarter of 2022.
Danaher (DHR) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Danaher (DHR) closed the most recent trading day at $255.05, moving +1.01% from the previous trading session.
Danaher (DHR) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Danaher (DHR) closed at $262.27, marking a -1.19% move from the previous day.
Why Danaher (DHR) Could Beat Earnings Estimates Again
by Zacks Equity Research
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Find Strong Multi-Sector Conglomerates Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Danaher (DHR) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Danaher (DHR) closed the most recent trading day at $260.88, moving +0.39% from the previous trading session.
Top Analyst Reports for AbbVie, PepsiCo & Oracle
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), PepsiCo, Inc. (PEP) and Oracle Corporation (ORCL).
Danaher (DHR) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Danaher (DHR) closed the most recent trading day at $255.60, moving -1.21% from the previous trading session.
Danaher (DHR) Up 14% in 6 Months: What's Driving the Stock?
by Zacks Equity Research
Danaher (DHR) gains from strength across its core Life Sciences segment, benefits from the DBS initiatives and acquired assets. The company's efforts to add shareholder value hold promise.
Danaher (DHR) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Danaher (DHR) closed at $274.23, marking a -0.89% move from the previous day.
Danaher (DHR) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Danaher (DHR) closed the most recent trading day at $271.82, moving +1.33% from the previous trading session.
Danaher (DHR) Stock Moves -0.11%: What You Should Know
by Zacks Equity Research
In the latest trading session, Danaher (DHR) closed at $274.23, marking a -0.11% move from the previous day.
GE (GE) Up 16.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
GE (GE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Danaher (DHR) Just Reclaimed the 200-Day Moving Average
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?
Here's How Much a $1000 Investment in Danaher Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
The Zacks Analyst Blog Highlights Danaher, Comcast, Starbucks, The TJX Companies and Stryker
by Zacks Equity Research
Danaher, Comcast, Starbucks, The TJX Companies and Stryker are part of the Zacks top Analyst Blog.
Q3 Earnings Season Scorecard and Analyst Reports for Danaher, Comcast & Starbucks
by Sheraz Mian
Today's Research Daily features a real-time update on the Q3 earnings season and new research reports on Danaher (DHR), Comcast (CMCSA) and Starbucks (SBUX).
Danaher's (DHR) Q3 Earnings Beat, Up Y/Y on Higher Sales
by Zacks Equity Research
Danaher's (DHR) Q3 results benefit from higher revenues across all segments. Organic sales rise 10%, while acquisition//divestitures boost sales by 1.5%.
Danaher (DHR) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Danaher (DHR) delivered earnings and revenue surprises of 14.29% and 8.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Danaher (DHR) Ahead of Earnings?
by Zacks Equity Research
Danaher (DHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can Danaher (DHR) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3M (MMM) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
3M (MMM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Danaher (DHR) Stock Moves -1.38%: What You Should Know
by Zacks Equity Research
In the latest trading session, Danaher (DHR) closed at $253.71, marking a -1.38% move from the previous day.
Will Cost Woes be a Spoiler for Danaher's (DHR) Q3 Earnings?
by Zacks Equity Research
High raw material costs and supply chain disruptions are likely to have hurt Danaher's (DHR) Q3 earnings. However, the top line is expected to have benefited from strong segmental performances.
Danaher (DHR) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Danaher (DHR) closed at $251.68 in the latest trading session, marking a -0.97% move from the prior day.